menu
    • menu
    [{"orgOrder":0,"company":"Sperogenix Therapeutics","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sperogenix Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Sperogenix Therapeutics \/ Santhera Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sperogenix Therapeutics \/ Santhera Pharmaceuticals"},{"orgOrder":0,"company":"Sperogenix Therapeutics","sponsor":"Minoryx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Leriglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Neurology","graph2":"Phase III","graph3":"Sperogenix Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Oral Suspension","sponsorNew":"Sperogenix Therapeutics \/ Sperogenix Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Sperogenix Therapeutics \/ Sperogenix Therapeutics"},{"orgOrder":0,"company":"Sperogenix Therapeutics","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sperogenix Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Suspension","sponsorNew":"Sperogenix Therapeutics \/ Sperogenix Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Sperogenix Therapeutics \/ Sperogenix Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Sperogenix Therapeutics

    Menu

    Sperogenix Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sperogenix Therapeutics

                            China arrow
                            ChemOutsourcing
                            Not Confirmed

                            Sperogenix Therapeutics

                            China arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vamorolone

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Santhera Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Santhera Launches AGAMREE® Early Access in China by its Partner Sperogenix

                            Details : Agamree (vamorolone) is a novel drug with a mode of action based on binding to the same receptor as glucocorticoids. It is approved for the treatment of duchenne muscular dystrophy.

                            Product Name : Agamree

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 06, 2024

                            Lead Product(s) : Vamorolone

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Santhera Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sperogenix Therapeutics

                            China arrow
                            ChemOutsourcing
                            Not Confirmed

                            Sperogenix Therapeutics

                            China arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vamorolone

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : Santhera Pharmaceuticals

                            Deal Size : $20.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Santhera Enters into Exclusive License Agreement with Sperogenix for Vamorolone in Rare Diseases in the Greate...

                            Details : Under the terms of the agreement, Santhera will grant Sperogenix Therapeutics exclusive development and commercialization rights to vamorolone in DMD and all other rare disease indications for Greater China (including mainland China, Hong Kong, Macau, an...

                            Product Name : Agamree

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 01, 2022

                            Lead Product(s) : Vamorolone

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : Santhera Pharmaceuticals

                            Deal Size : $20.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sperogenix Therapeutics

                            China arrow
                            ChemOutsourcing
                            Not Confirmed

                            Sperogenix Therapeutics

                            China arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leriglitazone

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Recipient : Minoryx Therapeutics

                            Deal Size : $78.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Minoryx Therapeutics and Sperogenix Therapeutics Sign License Pact to Develop and Commercialize Leriglitazone ...

                            Details : Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 23, 2020

                            Lead Product(s) : Leriglitazone

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Minoryx Therapeutics

                            Deal Size : $78.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth